NASDAQ:TVTX Travere Therapeutics (TVTX) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free TVTX Stock Alerts $7.71 +0.04 (+0.52%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$7.41▼$7.9750-Day Range$7.18▼$9.3252-Week Range$5.25▼$23.17Volume776,017 shsAverage Volume1.14 million shsMarket Capitalization$586.73 millionP/E RatioN/ADividend YieldN/APrice Target$17.85 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Travere Therapeutics alerts: Email Address Travere Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside131.5% Upside$17.85 Price TargetShort InterestBearish13.23% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.68Based on 5 Articles This WeekInsider TradingSelling Shares$439,024 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.10) to ($1.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.64 out of 5 starsMedical Sector494th out of 938 stocksPharmaceutical Preparations Industry233rd out of 430 stocks 4.3 Analyst's Opinion Consensus RatingTravere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 9 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.85, Travere Therapeutics has a forecasted upside of 131.5% from its current price of $7.71.Amount of Analyst CoverageTravere Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.23% of the outstanding shares of Travere Therapeutics have been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Travere Therapeutics has recently decreased by 1.85%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTravere Therapeutics does not currently pay a dividend.Dividend GrowthTravere Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TVTX. Previous Next 2.6 News and Social Media Coverage News SentimentTravere Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Travere Therapeutics this week, compared to 3 articles on an average week.Search Interest4 people have searched for TVTX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $439,024.00 in company stock.Percentage Held by InsidersOnly 3.75% of the stock of Travere Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Travere Therapeutics are expected to grow in the coming year, from ($3.10) to ($1.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Travere Therapeutics is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Travere Therapeutics is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTravere Therapeutics has a P/B Ratio of 2.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Travere Therapeutics Stock (NASDAQ:TVTX)Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Read More TVTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TVTX Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comTravere Therapeutics' (TVTX) "Neutral" Rating Reaffirmed at GuggenheimMarch 13, 2024 | globenewswire.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics on Strong FILSPARI Data and Favorable Regulatory OutlookMarch 13, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring Travere Therapeutics Through Analyst InsightsMarch 11, 2024 | markets.businessinsider.comTravere Therapeutics Submits SNDA Seeking Full Approval Of Filspari In IgA NephropathyMarch 11, 2024 | markets.businessinsider.comTravere Therapeutics Submits SNDA Seeking Full Approval Of Filspari In IgA NephropathyMarch 11, 2024 | globenewswire.comTravere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.February 28, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Moderna (MRNA) and Travere Therapeutics (TVTX)February 26, 2024 | globenewswire.comTravere Therapeutics to Present at Upcoming Investor ConferencesFebruary 23, 2024 | markets.businessinsider.comBuy Rating Affirmed: Expanding Market Potential for Travere Therapeutics’ SparsentanFebruary 23, 2024 | msn.comTravere drug for rare kidney condition recommended for EU approvalFebruary 23, 2024 | globenewswire.comTravere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA NephropathyFebruary 18, 2024 | finance.yahoo.comTVTX Mar 2024 30.000 callFebruary 16, 2024 | finance.yahoo.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2023 Earnings Call TranscriptFebruary 16, 2024 | markets.businessinsider.comDeep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings)February 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Travere Therapeutics (TVTX) and Grifols SA (GRFS)February 15, 2024 | msn.comTravere (TVTX) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesFebruary 15, 2024 | finance.yahoo.comTravere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 15, 2024 | globenewswire.comTravere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 15, 2024 | msn.comTravere Therapeutics Q4 2023 Earnings PreviewFebruary 13, 2024 | msn.comAxsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?February 8, 2024 | finance.yahoo.comTravere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsFebruary 1, 2024 | finance.yahoo.comTravere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology ConferenceJanuary 29, 2024 | seekingalpha.comTravere Therapeutics: Restructuring Away From DisasterJanuary 29, 2024 | markets.businessinsider.comStrategic Partnerships and Regulatory Advancements Anchor Buy Rating for Travere TherapeuticsSee More Headlines Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today3/29/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TVTX CUSIPN/A CIK1438533 Webwww.retrophin.com Phone(888) 969-7879Fax302-645-1280Employees380Year FoundedN/APrice Target and Rating Average Stock Price Target$17.85 High Stock Price Target$35.00 Low Stock Price Target$9.00 Potential Upside/Downside+131.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-111,400,000.00 Net Margins-56.02% Pretax Margin-258.96% Return on Equity-177.97% Return on Assets-44.19% Debt Debt-to-Equity Ratio1.88 Current Ratio3.47 Quick Ratio3.41 Sales & Book Value Annual Sales$145.24 million Price / Sales4.04 Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book2.89Miscellaneous Outstanding Shares76,100,000Free Float73,244,000Market Cap$586.73 million OptionableOptionable Beta0.58 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Eric M. Dube Ph.D. (Age 50)President, CEO & Director Comp: $1.35MMr. Christopher Cline C.F.A. (Age 39)Chief Financial Officer Comp: $634.36kDr. William E. Rote Ph.D. (Age 61)Senior VP and Head of Research & Development Comp: $733.25kMr. Peter Heerma (Age 53)Chief Commercial Officer Comp: $705.62kDr. Jula Inrig M.D. (Age 49)Chief Medical Officer Comp: $815.93kMs. Sandra Calvin (Age 58)SVP, Corporate Controller & Chief Accounting Officer Ms. Naomi EichenbaumVice President of Investor RelationsMs. Elizabeth E. Reed (Age 53)Senior VP, General Counsel & Corporate Secretary Comp: $696.68kMs. Charlotte SmithSenior Vice President of Public AffairsMs. Angela GiannantonioSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsCOMPASS PathwaysNASDAQ:CMPSGH ResearchNASDAQ:GHRSAnaptysBioNASDAQ:ANABArriVent BioPharmaNASDAQ:AVBPFulcrum TherapeuticsNASDAQ:FULCView All CompetitorsInsiders & InstitutionsHealthcare of Ontario Pension Plan Trust FundBought 635,277 shares on 3/21/2024Ownership: 0.835%Vanguard Group Inc.Bought 847,685 shares on 3/11/2024Ownership: 7.247%Wellington Management Group LLPBought 141,994 shares on 3/5/2024Ownership: 0.187%Virtu Financial LLCBought 19,498 shares on 2/26/2024Ownership: 0.026%Quarry LPSold 5,500 shares on 2/20/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions TVTX Stock Analysis - Frequently Asked Questions Should I buy or sell Travere Therapeutics stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TVTX shares. View TVTX analyst ratings or view top-rated stocks. What is Travere Therapeutics' stock price target for 2024? 15 Wall Street analysts have issued twelve-month price objectives for Travere Therapeutics' stock. Their TVTX share price targets range from $9.00 to $35.00. On average, they predict the company's share price to reach $17.85 in the next twelve months. This suggests a possible upside of 131.5% from the stock's current price. View analysts price targets for TVTX or view top-rated stocks among Wall Street analysts. How have TVTX shares performed in 2024? Travere Therapeutics' stock was trading at $8.99 on January 1st, 2024. Since then, TVTX stock has decreased by 14.2% and is now trading at $7.71. View the best growth stocks for 2024 here. When is Travere Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our TVTX earnings forecast. How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:TVTX) announced its quarterly earnings data on Thursday, February, 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.11. The business earned $45.06 million during the quarter, compared to the consensus estimate of $41.25 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 177.97% and a negative net margin of 56.02%. What ETFs hold Travere Therapeutics' stock? ETFs with the largest weight of Travere Therapeutics (NASDAQ:TVTX) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI) and ALPS Medical Breakthroughs ETF (SBIO).Direxion Daily S&P Biotech Bull 3x Shares (LABU). Who are Travere Therapeutics' major shareholders? Travere Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (9.83%), Vanguard Group Inc. (7.34%), Vanguard Group Inc. (7.25%), Kynam Capital Management LP (2.66%), Finepoint Capital LP (1.91%) and Parkman Healthcare Partners LLC (1.36%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote. View institutional ownership trends. How do I buy shares of Travere Therapeutics? Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TVTX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.